Abstract
Introduction
Neuropeptide Y (NPY) is a 36-amino acid, C-terminal amidated polypeptide first isolated from porcine brain by Tatemoto's group in 1982. 1 It is a member of the NPY peptide family along with pancreatic polypeptide (PP, isolated in 1983) 2 and peptide YY (PYY, isolated in 1980) 3 , which both share a high degree of homology in amino acid sequence. The physiological functions of NPY are mediated by Y receptors, belonging to the rhodopsin-like Gi coupled Gprotein coupled receptor (GPCR) family and four subtypes, Y1R, Y2R, Y4R and Y5R have been identified in humans. [4] [5] [6] Y1R is expressed abundantly in both central and peripheral sympathetic nervous systems, and the NPY/Y1R signalling cascade is implicated in various physiological responses, including regulation of feeding behaviour, 7, 8 stimulation of ethanol intake, 9, 10 vasoconstriction 11, 12 and initiation of anxiety and depression. 13, 14 In addition, breast carcinomas, including primary tumours and lymph node metastases, have also been found to over-express Y1R. 15 This suggests that Y1R may be responsible in tumour proliferation, apoptosis, metastasis and angiogenesis. 16 With Y1R being a potential drug target, traceable high affinity Y1R ligands are highly desirable tools for studying the localisation, regulation and function of this receptor. Lys 4 (sCy5)-NPY was shown to be an agonist of Y1R, Y2R and Y4R receptors, and of utility in the development of FACS-based functional assays of complex cell-based assay systems. 17 Another approach has been to derive fluorescent or radiolabelled analogues of the Y1R arginamide antagonist series (BIBP3226, BIBO3304), 18 including pyridinium and cyanine based BIBP3226 derivatives suitable for fluorescent imaging. 19, 20 . An alternative starting point has made use of smaller NPY derived peptide ligands, such as the competitive Y1R antagonist / Y4R agonist BVD-15 (or BW1911U90), a nonapeptide modified from the NPY C-terminal fragment (
Figure 1
. 21 This peptide has been amenable to conjugation with a variety of radiolabels and fluorophores. In particular, Gueŕin et al. showed that the Ileconjugated Lys to incorporate DOTA, NOTA or fluorine moieties, 22, 23 and we extended this result to include a rhodamine fluorophore. 24 No less notably, the Lys 4 substitution itself resulted in increased affinity, 23 and other basic residues were also well tolerated. 24 This prompted us to examine such analogues with Pro 3 as a point of conjugation and we have recently described propargyloxyproline containing Lys 4 -and Arg 4 -BVD-15 that could incorporate rhodamine B and 7-aminocoumarin fluorophores. 25 The tyrosine at the 5-position has been also shown to be capable of replacement with a conjugate group. 26 Noting that the position and nature of the conjugated group and its linkage could have a significant influence on the pharmacology of the resulting peptide, here we have examined the 
Results and Discussion

Chemistry
We began by expanding our pool of conjugate precursors to include a variety of rhodamine B (RhB) conjugates (Figure 2) , taking advantage of the capacity to generate different linkers from a common, inexpensive precursor, 27 as well as two cyanine dyes (Figure 2 ) Cy5.5 and sulfo-Cy5 (sCy5). We extended the types of conjugates included at Lys 4 , but also encompassed substitutions at Asn 2 . While a lysine residue at the 2-position had been shown to be detrimental to Y1R activity, 23 the influence on subsequent conjugation had not been tested.
The synthesis of the conjugated BVD-15 analogues was achieved by one of three distinct methods. While all peptide backbones were prepared by adapting standard Fmoc-based solid phase peptide synthesis (SPPS) strategy, both solid and solution phase side-chain labelling were attempted. To facilitate chemoselective derivatisation at the 2-position, the 4-position was substituted by an Arg residue, which retains high affinity for Y1R receptors. In the first instance, linear peptides were synthesised with N-terminal Fmoc protection and amide coupling in solution was achieved using carboxyl-functionalised fluorophores, followed by Fmoc-deprotection to yield the target peptides (analogues A, D, F and H, using Method 1 in Scheme 1. In Method 2, selective ε-amine modification on solid phase was achieved by incorporating ε-Mtt-protected Lys as an orthogonal protection. The Mtt group was selectively cleaved off by treating with 25% HFIP and 5% TIPS, and then the Cy5.5 fluorophore was coupled as an N-succinimidyl ester. The N-terminal Fmoc group was removed by 20% piperidine prior to the final acidolytic cleavage, giving analogues E and G. In order to prepare analogues B and C where conjugates are linked by the 1,2,3-triazole group, Fmoc-Lys(azide)-OH was incorporated at the 4-position. Labelling was then achieved by solution phase CuAAC reaction using the alkyne-containing RhB-2 and RhB-3, in presence of CuSO4 and sodium ascorbate as the catalysts (Method 3). 25 The synthesised analogues with their analytical data are summarised in Table 1 . 
Pharmacological analysis of NPY analogues
We examined the functional properties of the BVD-15 analogues as antagonists of NPYinduced Y1R engagement with β-arrestin2, a GPCR effector protein involved in G protein independent signalling and agonist induced receptor desensitisation and internalisation. 28 Figure 3A ) with a pA2 of 7.5, and all but one of the labelled ligands showed comparable high affinity antagonism. pKb values were calculated from NPY concentration response curve shifts in the presence of a single antagonist concentration (100 nM or 300 nM; Figure S1 ), and ranged from 6.9 to 7.9 with the rhodamine-linked triazole compound B showing highest affinity ( Table 2) . Of the four cyanine labelled derivatives, three were antagonists ( Figure 3B ).
Interestingly, substitution of the sCy5 fluorophore for Cy5.5 at the same 2-position led to compound G showing partial agonism in the Y1R arrestin recruitment assay, with a pEC50 of 7.04 ± 0.19 and a maximal response of 52.8 ± 4.8% compared to that elicited by 1 µM NPY (n = 3; Figure S2 ). In contrast, analogues E, F (both cyanine labelled at 4-position) and H showed no agonism at concentrations up to 1 µM. determined by this method were consistent with our other whole cell data. . Pooled competition binding data (Panel C-E, at least 3 experiments) were derived from granularity analysis of the ligand images, normalised to total specific binding (100%). In C, BIBO3304 competition curves were performed at three H concentrations; the plot of the BIBO3304 IC50 versus ligand concentration (inset) provides additional Ki affinity estimates for both BIBO3304 and H quoted in text (see Materials and Methods). pKi estimates were also obtained for a range of agonist peptides (Panel D) and antagonists (Panel E), as indicated in Table 4 .
Peptide H was employed in the study of a range of known Y receptor agonists, antagonists as well as a series of analogues prepared in related studies (Table 3) . 29, 31 The expected Y1-like pharmacology in the competition assay was observed for agonist peptides ( Figure 5D ; NPY = [Leu31, Pro34]NPY ≥ PYY > PYY3-36 = PP), as previously described for many Y1 receptor systems, 32 and also antagonists, such as the dimeric peptide 1229U91. 29 The order of affinity based on pKi values from these experiments was consistent with [125I]PYY binding assays for representative ligands performed in Y1R-GFP cell membranes (and previously described data from Y2Y4 receptor knockout mice). 29 For the non-peptide antagonist BIBO3304 there was good correspondence between affinities measured in these formats, and also functional measurements previously reported. 28 For the peptide ligands the actual pKi values for the whole cell assays were consistently lower than for membrane based assays ( Table 4 ). The reason for this discrepancy is not obvious, but note that there is a closer correlation between the competition binding (pKi) and the functional antagonism in the whole cell system. The difference may be due to the buffer conditions in routine Y receptor membrane binding assays (low sodium and absence of guanine nucleotides) that are designed to promote the high affinity ternary receptor complex, and maximize radiolabelled agonist peptide binding. 33 The nonphysiological buffer cation concentrations might also directly affect peptide ligand binding to the receptor. Thus one of the important advantages of our measurements using fluorescent antagonist binding to whole cells, in physiological buffer, is that the affinities obtained should closely correspond to observations from functional data, particularly for agonists. Indeed the estimates of agonist affinity by this route ( Figure 5D ) do closely correspond with their potencies in Y1R-arrestin recruitment assay previously reported, 28 as anticipated for a response with limited receptor reserve. 33 We also assayed compounds for which we had membrane competition binding data spanning a range of affinities, including analogues of 1229U91, I and J ( Figure 5E ; Table 3 ) 29 and some unlabeled BVD-15 analogues K -N ( Table 3 ) and found the same trends (Table 4, Figure   S3 ). 2+ . c. HPLC retention time using a Phenomenex Luna C-8 column (100Å, 3µm, 100×2.00mm). The gradient is composed of 100% H2O (0.1% TFA) for 4 min, 0-60% acetonitrile in H2O (0.1% TFA) over 10 min, and isocratic 60% acetonitrile in H2O (0.1% TFA) for 1 min. Detection wavelength = 214 nm. Compound H displayed moderate affinity for Y4R (Figure 6) , with saturation binding assays yielding a pKD for H of 6.26 ± 0.11 (n = 4), 8 fold lower than for Y1R. It did not bind cells expressing Y2R or Y5R (data not shown) at up to 1 µM, as might be predicted from the reported selectivity profile for BVD-15. 35 In contrast to its actions at the Y1R, H was a Y4R partial agonist, a property shared by BVD-15, in the β-arrestin2 recruitment assay (Figure 6 ; pEC50 = 7.10 ± 0.19, 1 µM response 59.0 ± 3.6 %, 100 nM PP, n = 6); other cyanine BVD-15 analogues E-G displayed limited Y4R agonism at the highest concentration tested (1 µM). At 100 nM, H selectively labelled 293TR cells expressing Y4R-GFP (Figure 6A) , enabling competition binding studies to derive pKi estimates for human PP, 1229U91 and its analogues I and J ( Figure 6C ; Table 4 ). As previously discussed, these estimates were lower than those previously reported for [ 125 I]PP agonist binding studies in Y4R containing membranes. Table 4 were determined. In the Y4R-β-arrestin2 recruitment assay (Panel D), H was a partial agonist compared to PP, but of higher relative efficacy than 1229U91 (pooled data 4-10 experiments).
FBz = 4-fluorobenzoyl, O = ornithine, F* = Phe(4-CH2NH-FBz).
In summary, our studies of fluorescent labelling of the BVD-15 scaffold has allowed us to identify some new features of the peptides structure-activity relationships. First, we confirmed the general tolerance for modification at the 4-position, with retention of antagonistic activity at levels similar to the parent peptide in the presence of rhodamine derivatives and cyanine dyes. Second, we showed for the first time that the Asn residue at 2-position, in combination with introduction of an Arg at 4-position yields peptides with retained affinity. However, while the sulfated Cy5 (sCy5) ligand is an antagonist, the more hydrophobic Cy5.5 label has agonist properties. This is significant as only one other example of a truncated NPY analogue has been shown to be an agonist. 26 We have also shown that analogue H is an excellent ligand for performing receptor binding studies at Y1R in intact cells using high content imaging, with low levels of non-specific binding. Finally, we also show that analogue H has Y4R agonism, albeit at a lower level of affinity compared to Y1R binding. Thus analogue H is also a suitable ligand for conducting competition binding and functional assays against Y4R and has been applied recently in structure-activity studies of the dimeric Y4 agonist, BVD-74D 36, 37 . The ready synthesis of this fluorescent ligand and its favourable properties will be of great utility in the development of new ligands for these two important receptors. University). The Rhodamine B derivatives were prepared in-house from the commercially available product (Sigma-Aldrich), according to Nguyen and Francis. 27 All solvents were of analytical grade, and all chemicals were used without further purification.
Experimental Methods
Material
Molecular mass of peptides was determined by ESI-MS using a Shimadzu LCMS2020 instrument, incorporating a Phenomenex Luna C-8 column (100Å, 3μm, 100×2.00mm).
Detection wavelength was set at 214 nm. This system used 0.05% TFA in MilliQ water as the aqueous buffer, and 0.05% TFA in acetonitrile as the organic buffer. The eluting profile was a linear gradient of 0-60% acetonitrile in water over 10 min at 0.2 ml/min.
Crude peptides were purified on a Phenomenex Luna C-8 column (100Å, 10μm, 250×21.2mm) utilising a Waters 600 semi-preparative RP-HPLC that incorporates a Waters 486 UV detector.
Detection wavelength was set at 230 nm. This system used 0.1% TFA in MilliQ water as the aqueous buffer, and 0.1% TFA in acetonitrile as the organic buffer. The eluting profile was a linear gradient of 0-80% acetonitrile in water over 60 min at 10 ml/min.
Peptide synthesis
General synthesis
Linear peptides (0.1 mmol scale) were synthesised on Rink amide resin using a 3-channel serial automated peptide synthesiser ("PS3", Protein Technologies Inc.), which adopted standard Fmoc-based solid phase synthesis strategy. Fmoc deprotection was performed by piperidine (20% v/v) in DMF for 2×5 min. Fmoc protected amino acids (3 eq.) were coupled using DMF as solvent, and DIPEA in DMF (7% v/v) with HCTU (3 eq.) as the activating agent for 50 min.
Protected peptidyl-resins were cleaved by treating with a cocktail (5 ml) composed of TFA-TIPS-DMB (92.5%:2.5%:5%) for 3 h. The cleavage mixture was then filtered, concentrated by stream of N2, precipitated in cold Et2O and centrifuged at 3000 rpm for 5 min. The crude product was dissolved in water-acetonitrile mixture (50%:50%) and lyophilised.
Labelling methods
Method 1:
The N α -Fmoc protected linear peptide dissolved in DMF (0.6 ml) was treated with carboxyl-functionalised fluorophore of interest (1.2 eq.), PyClock (2 eq.) and NMM (12 eq.) overnight. After DMF was removed in vacuo, the product was washed by TFA (1 ml), precipitated by cold Et2O and centrifuged at 3000 rpm for 5 min. The N α -Fmoc group was then removed by piperidine (20%) in DMF (5 ml) for 30 min and the reagents were evaporated in vacuo. The product was re-dissolved in water-acetonitrile (50%:50%) and lyophilised.
Method 2:
The protected peptidyl-resin containing a Lys(Mtt) residue was treated with HFIP (25%) and TIPS (5%) in DCM (5 ml) for 30 min to selectively remove the Mtt group. Cy5.5
(as an N-succinimidyl ester) was conjugated by treating overnight in an alkaline condition created by DIPEA (10 eq.). Peptides were purified by RP-HPLC as described above. The purity of all peptides are ≥ 93%
according to the HPLC chromatographs produced by the ESI-MS method described above, and MS data corresponded to the expected m/z values. Additional details are provided in Table 1 , comprised less than 5% of total counts, and was subtracted from the data.
In both sets of data, IC50 values were calculated from displacement curves (repeated 2-3 times for each peptide, fitted using non-linear least squares regression in GraphPad Prism v6
(GraphPad software, San Diego CA, U.S.A). They were converted to pKi estimates using the Cheng-Prusoff relationship:
where [RL] and KRL represent the concentration and equilibrium dissociation constant of Competition data were normalised to positive (totals 100 %) and negative (0%, in presence of either 1 µM NPY or 100 nM PP as appropriate) controls. For saturation studies, total and nonspecific binding data were globally fitted using a one site binding model whereby:
Total binding = . 
